BioVersys AG to present at H. C. Wainwright Global Investment Conference

BioVersys AG, a clinical-stage biopharmaceutical company specializing in antibacterial products for multi-drug resistant infections, has announced its participation in the H. C. Wainwright 28th Annual Global Investment Conference in New York City.

Chief Financial Officer Hernan Levett is scheduled to present a corporate overview on September 16, 2026. Additionally, Chief Executive Officer Dr. Marc Gitzinger will participate in an on-demand session on September 11, 2026. The company's leadership will also be available for meetings during the conference held from September 14-16.